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Background: Despite the use of combination antiretroviral therapy, HIV associated 
neurocognitive impairment (NCI) persists in HIV seropositive persons, albeit in milder forms than 
before therapy was available. Nevertheless, the relationship between NCI and health-related 
quality of life (HRQoL) is not well known.  
Method: Baseline data from the CHARTER study was used to investigate the association 
between NCI and HRQoL. Factor analysis was employed to summarize the 35-item Medical 
Outcome Survey questionnaire into physical and mental HRQoL scores. General linear models 
were employed to investigate the association between NCI, as measured by global deficit scores 
(GDS), and HRQoL, and to control for confounding.  
Results: A total of 1,340 HIV participants were analyzed, including 35.6% NCI, 77.2% males, 
70.5% unemployed, and 42.2% depressed. The mean (standard deviation) mental HRQoL scores 
(lower scores are worse) for impaired and unimpaired participants were 64.0 (18.4) and 67.9 
(18.6) and mean physical HRQoL scores for impaired and unimpaired participants were 60.3 
(24.7) and 65.1 (25.9), respectively. There  was an inverse  association between NCI and mental 
HRQoL in unadjusted [-4.38 (-6.70 to -2.06)] and adjusted analysis [-2.56 (-4.83 to -0.30)],  
controlling for unemployment and current psychotropic medication use. The association between 
NCI and physical HRQoL  was significant in unadjusted analysis [-4.62 (-7.45 to -1.78)] but not in 
adjusted analysis [2.20 (-4.81 to 0.40)], controlling for unemployment, CD4 nadir and positive 
opiate test results and other covariates. 
Conclusion. The inverse association between NCI and HRQoL was confounded mainly by 
employment and mediated by depression. Interventions aimed at the comprehensive treatment 
of HIV patients should include the management of depression and maintenance of employment.  
Key Words: Neurocognitive impairment. Quality of life. Medical outcome survey questionnaire. 




HIV-1 enters the brain early during infection [1] when infected monocytes, lymphocytes [2] or viral 
particles cross the blood brain barrier (BBB) [3]. The virus can then infected macrophages and 
microglia in the central nervous system (CNS) and cause immune activation and indirect damage 
to neurons [3, 4].  
HIV-1 replication and continuous immune activation in the CNS causes alterations in brain 
structure, the degeneration of brain cells and alterations in brain gray and white matter volume, 
and brain abnormalities [5]. Persistent immune activation can result in immune dysfunction, 
neuro-inflammation, and injury to synapses and dendrites [1, 6, 7]. Injury to synapses affects the 
functioning of neurotransmitters, the transmission of electrical impulses from one neuron to the 
other, and may contribute to neurocognitive impairment, neuropathy and decline in health-related 
quality of life [1, 8, 9]. Although the introduction of combination antiretroviral therapy (cART) in 
the late 1990s has resulted in decreased HIV related mortality, morbidity and HIV related 
dementia, mild to asymptomatic forms of HIV associated neurological disorders (HAND) remain 
a problem [11]. HAND may be due to the direct neurotoxic effects of combination antiretroviral 
therapy (cART) that cause neuronal damage or dysfunction [1]. Additionally, once macrophages 
and microglial cells are infected, they serve as reservoirs for the virus in the brain where it can 
continue to replicate, evading HIV-drugs with limited CNS penetration [12].  
HIV in the CNS and the neurotoxic effect of cART are not the only risk factors for cognitive 
impairment and the associated impact on quality of life of HIV patients. Studies have shown that 
substance abuse and drug use aggravate the deleterious effect of HIV on brain metabolites [13], 
lead to neuronal injury [14] and negatively affect neuropsychological functioning [15]. Hepatitis C 
virus coinfection is associated with cognitive impairment and domain specific dysfunction [16, 17]. 
HIV positive individuals with a syphilis co-infection or history of prior syphilis infection are at 
increased risk of neurocognitive impairment and neuropsychological dysfunction compared to HIV 
negative individuals with no history of syphilis [18, 19]. Cardiovascular risk factors associated with 
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aging can influence cognitive dysfunction particularly slowing of psychomotor speed and cognitive 
performance [2]. Coronary heart disease increases the likelihood of developing cognitive 
impairment [20, 21]. Depression, hypertension, physical inactivity, diabetes, obesity, 
hyperlipidemia, and smoking are strong risk factors for dementia [22]. A higher body mass index 
(BMI) is associated with cognitive dysfunction in healthy individuals [23, 24], alterations in cortical 
gray and white matter volumes [25] and slower processing speed [26]. Dyslipidemia caused by 
high LDL cholesterol and triglyceride concentrations in the blood is associated with sensory 
neuropathy and cognitive impairment in people infected with HIV [27]. Psychiatric disorders have 
a deleterious effect on cognitive function [28-31] and psychotropic drug use may negatively affect 
memory, attention, psychomotor performance and cognitive function [32]. Age has effect on brain 
gray and white matter volume and results in degeneration of brain cells [33]. Additionally, genetic 
factors such as polymorphisms in host immune response genes have been associated with CNS 
inflammation and the effect of antiretroviral therapy on viral replication, suppression and side-
effects on the brain [34].  
The deleterious effect of HIV infection and associated comorbidities on quality of life of 
HIV participants are well documented [19, 28, 35-39]. Nevertheless, few studies have investigated 
the relationship between HIV-associated neurocognitive impairment (NCI) and health-related 
quality of life or the neurotoxic effects of cART on health-related quality of life in HIV participants. 
We analyzed the Central Nervous System HIV Antiretroviral Therapy Effects Research 
(CHARTER) study to investigate the relationship between HIV-associated NCI and health-related 
quality of life (HRQoL). An understanding of the predictors of HRQoL of HIV participants with NCI 
can contribute to the knowledge based necessary to inform comprehensive HIV management.  
Study Objectives 
 The main objective of this study was to examine the relationship between 
neurocognitive impairment, as measured by global deficit scores (GDS), and HRQoL using 
baseline data from the CHARTER study. We hypothesized that HIV-associated (NCI) is 
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associated with HRQoL and there is a significant difference in HRQoL between impaired and 
unimpaired participants. A secondary objective of this analysis was to determine whether the 
Medical Outcome Survey (MOS) questionnaire can be summarized into physical and mental 
health summary scores using factor analysis. 
Methods 
Data Source and Participants 
We analyzed data from the CHARTER study, a prospective, observational study 
conducted from 2004 to 2015 in three phases [18, 42]. The primary aim of the CHARTER study 
was “to determine how central and peripheral nervous system complications of HIV are affected 
by different histories and regimens of antiretroviral therapy” (https://charternntc.org/). The study 
design is described in detail in [42, 44]. Baseline data collected from 2004 to 2007 at the time of 
recruitment was analyzed. All participants for this study were HIV infected individuals recruited 
from six university research clinics in the United States [42, 44]. The Institutional Review Board 
of each participating Institution reviewed and approved the study [44]. 
The CHARTER study used a volunteer sample. A total of 2,016 HIV participants that 
attended a clinic at the participating university centers were screened at baseline and invited to 
participate in the study, with minimal exclusion criteria [42, 43]. Participants were excluded from 
the study only if they declined to participate or if they could not complete the assessment at the 
time of evaluation [42, 44]. Of the participants screened, 40 (2.0%) were not asked to continue 
while 366 (18.2%) declined to participate. Cross sectional baseline data were collected from 1,610 
HIV infected participants from six centers. For the current study, 1,587 participants who had 
complete data on HRQoL were included in the factor analysis. Participants with missing data on 
study variables and those with confounding comorbidities were excluded from the final analysis 
(Figure 1). Confounding comorbidities were determined based on expert ratings of the comorbidity 
status of participants in all six centers using standard guidelines [44]. All participants were 
classified as having incidental, contributing or confounding comorbidities. “Confounding 
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conditions that could fully explain significant neuropsychological impairment and currently 
observed problems with everyday functioning” [44] preclude the attribution of NCI solely to the 
effects of HIV on the brain so persons with confounding comorbidities were removed from the 
analysis [44]. 
Dependent and Independent Variables  
HRQoL was measured by the standardized 35-item MOS questionnaire, which is based 
on patients’ self-reports of their subjective wellbeing [46]. The main outcome variables were 
physical and mental HRQoL summary scores derived from the questionnaire. The 35-item 
questionnaire was summarized into ten scales: pain, physical functioning, social functioning, 
mental health, energy or fatigue, health distress, cognitive functioning, general health, role 
functioning and quality of life scales. Previous studies have shown that these scales can be 
reduced into distinct physical and mental health summary scores for a sample of HIV participants 
[47]. Following procedures in [47], the 35-item questionnaire was reduced into physical and 
mental HRQoL summary scores, which served as the main outcome variables. The main 
independent variable was HIV-associated NCI as measured by GDS. Data to compute cognitive 
impairment were collected using a comprehensive set of neuropsychological tests covering seven 
cognitive domains [18]. Standard methods were used to compute cognitive impairment using GDS 
described elsewhere [44,45].  
Statistical Analysis 
Exploratory and confirmatory factor analysis was conducted to reduce the 35-item MOS 
questionnaire to physical and mental health dimensions. Factor analysis was based on a 
complete case analysis of 1,587 participants using SAS version 9.4, after deleting 23 (1.4%) 
cases with missing data. Data reduction to compute summary scores for the MOS questionnaire 
followed a three-step process. In the first step, eleven of the 35 items of the MOS questionnaire 
were reverse coded to ensure that higher scores reflect a more favorable health status. The 35 
items were then summarized into eleven scales by adding questionnaire items designed to 
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measure common constructs. The scales were; pain (2 items), physical functioning (6 items), role 
functioning (2 items), social functioning (1 item), mental health (5 items), energy or fatigue (4 
items), health distress (4 items), cognitive functioning (4 items), general health perception (5 
items), quality of life (1 item) and health transition (1 item). The scales were transformed to 0 to 
100 scores with 100 representing best health status [47]. In the second step, we performed 
exploratory factor analysis on a subsample of 794 participants representing half of the full dataset 
randomly selected from the total sample using the SAS PROC SURVEYSELECT procedure. The 
exploratory factor analysis procedure used squared multiple correlations as prior communality 
estimates. Two factors were extracted by the principal factor method followed by a promax 
rotation [48]. Health transition did not load on any factor, so it was not included in the confirmatory 
factor analysis. In the third stage, the extracted factors were validated using confirmatory factor 
analysis applied to the full dataset of 1,587 participants. A measurement model that describes the 
relationship between the 2 latent factors and the 10 scales was developed and confirmatory factor 
analysis was conducted to demonstrate that the model fits the data [48-51]. The maximum 
likelihood method (MLM) was used for parameter estimation.  
Model development followed a structured approach. We conducted comprehensive 
literature review that informed the development of a causal directed acyclic graph (DAG) 
exhibiting the theoretical relationships among potential confounders of the relationship between 
NCI and HRQoL. This information was used to identify potential confounders to be included in 
the model [52]. ‘Change- in-estimate’ approach was used to determine confounders to be 
included in the model. The aim was to derive the most accurate estimates ( as measured by 
mean square error) of the relationship between NCI and HRQOL and obtain a parsimonious 
model that controls most confounding [52]. Bivariate analysis using independent sample t-tests, 
Pearson correlation coefficients, and one-way analysis of variance (ANOVA) was conducted to 
investigate the relationship between NCI and candidate confounders and between HRQoL and 
candidate confounders. All variables associated with NCI (p = 0.10) and at the same time 
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associated with HRQoL (p = 0.10) were retained as potential confounders. A test for 
confounding was conducted in two steps. Firstly, the mean difference of the relationship 
between HRQoL (physical and mental) and NCI for a reduced model comprising of NCI, age, 
gender at birth and race/ethnicity was estimated. Secondly, potential confounders were added 
one after the other and the change in the estimate was observed for each variable added. If the 
percentage change in the estimate for the reduced model compared to the model with the 
added confounder was greater than 10%, we considered the variable as a confounder and 
included it in the model, if no it was ignored.  
Results 
Characteristics of Participants at Enrollment 
  Of the 1,857 participants with complete data on the outcome variable, 15.6% had severe 
comorbidities, 54.0% had incidental comorbidities while 30.0% had contributing comorbidities. 
Comorbid conditions included brain trauma, epilepsy, low reading levels, major depression, 
lifetime or current substance use or alcohol disorder to name but a few. Severe comorbidities 
confound NCI diagnosis so 247 participants with severe comorbidities were excluded from the 
study [44]. The final sample (n = 1,340) included 77.2% males, 46.9% Black or African Americans, 
41.1% Whites and 70.5% unemployed participants. The mean age was 43.0 years (SD = 8.65). 
Approximately one third of the participants were neurocognitively impaired as determined by their 
GDS scores (table 2). 
Factor Analysis 
The results of the exploratory factor analysis confirmed that two factors could be extracted 
from the 10 scales of the MOS questionnaire (the scale health transition did not load on any factor 
in exploratory factor analysis). The rotated factor pattern was used to determine scales that 
loaded on which factor. A scale was said to load on physical health and not on mental health if a 
factor loading of the scale was 0.4 or higher on the physical health factor but less than 0.4 on the 
mental health factor [48]. Five factors loaded on mental health and five factors loaded on physical 
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health. The factor pattern showed simple structure (i.e., no scale loaded on more than one factor). 
A review of the eigenvalues, proportion of variance explained, and the scree plots combined with 
the rotated factor pattern demonstrated that the MOS questionnaire can be summarized into two 
factors; mental health and physical health.  
Means, standard deviations and Pearson correlation coefficients for the 10 scales of the 
MOS questionnaire using the full sample were computed (table 1). The Pearson correlation 
coefficients ranged from 0.33 to 0.66, indicating a relatively strong positive association among the 
variables. The standardized path coefficients for the factor loadings are shown on figure 2. The t-
values for all standardized path coefficients were statistically significant (p < 0.001) and all the 
standardized path coefficients were greater than 0.65, providing support for the convergent 
validity of the scales [48].  
Differences in Clinical Characteristics Between HIV Impaired and Unimpaired Participants. 
The Mann Whitney test was conducted to determine whether there are differences between 
impaired and unimpaired participants on main clinical variables. Compared to unimpaired 
participants, impaired participants had higher median white blood cell count (Z = 2.12 , p = 0.034), 
lower hematocrit percentage in blood (Z = -2.10, p = 0.036), lower blood hemoglobin levels (Z = 
-2.09, p = 0.037 ), higher mean corpuscular (cell) volume (Z = 3.08, p = 0.002), higher alkaline 
phosphatase levels (Z = 2.81, p = 0.005), higher serum triglycerides (Z = 2.19, p = 0.029), higher 
white blood cell counts in cerebrospinal fluid (Z = -2.97, p < 0.003), and higher monocyte 
percentage in CSF (Z = 3.14, p = 0.001). Nevertheless, the average values were within normal 
clinical range for both impaired and unimpaired groups. 
Differences in HRQoL Between HIV Neurocognitive Impaired and Unimpaired Participants. 
The results of t-tests showed that unimpaired participants had higher physical (p = 
0.001) and mental HRQoL composite scores (p < 0.001) than impaired participants, with higher 
scores indicating better quality of life perception, less pain or role limitation. Specifically, 
unimpaired participants reported higher mean scores for mental health (p = 0.004), 
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energy/fatigue (p = 0.006), health distress (p = 0.001), cognitive function (p < 0.001), physical 
function (p < 0.001), role function (p = 0.002), and social function (p = 0.009) compared to 
impaired participants. However, impaired and unimpaired participants had similar quality of life 
perception (p = 0.175), pain (p = 0.164) and general health perception (p = 0.141).  
Confounders of the Relationship Between HIV-Associated Neurocognitive Impairment and 
HRQoL. 
In unadjusted analyses, the following were identified as potential confounders of the 
relationship between HIV associated neurocognitive impairment (NCI) and HRQOL at the 5% 
level of significance: gender at birth, race/ethnicity, employment, highly active antiretroviral 
therapy, lowest CD4 count (cells/mm3), current psychotropic medication use, life time alcohol 
abuse or dependence, current opiate test result, high cholesterol, cerebrospinal fluid (CSF) 
glucose, CSF total protein, hematocrit percentage (g/dl) in blood, hemoglobin (g/dl) in blood, 
mean corpuscular (cell) volume (x10^-15 L (fL)) in blood, basophil percentage in blood and serum 
alkaline phosphatase level (IU/L). Age and education where associated with physical but not 
mental HRQoL or impairment. The potential confounders that met the criteria for inclusion in the 
models for mental and physical HRQoL are shown on tables 2 and 3. 
The Relationship Between Impairment and Mental and Physical HRQoL in Adjusted 
Analysis. 
The relationship between mental health related quality of life (HRQoL) and HIV-associated 
NCI as measured by global deficit scores was significant in unadjusted and adjusted analysis. 
Impaired participants had lower mental health related quality of life compared to unimpaired 
participants. The association between NCI and HRQoL was lower in unadjusted [-4.38 (-6.70 to -
2.06)] than in adjusted analysis [-2.56 (-4.83 to -0.30)] and remain significant when controlled for 
age, gender at birth, race/ethnicity, unemployment and current psychotropic medication use. In 
adjusted analysis, female gender, white and Hispanic race/ethnicity, current unemployment or 
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part-time employment and current prescribed psychotropic medication use were associated with 
lower mental HRQoL (table 2).  
The association between NCI and physical HRQoL was significant in crude analysis [-4.62 
(-7.45 to -1.78)] but not significant when adjusted for gender, age, race/ethnicity, employment, 
lowest CD4 count (cells/mm3) and positive opiate test results [-2.20 (-4.81 to 0.40)]. In adjusted 
analysis, female gender, white race/ethnicity, ages 40 to 59, unemployment, lowest CD4 below 
500 cells/mm3 and positive opiate test results were associated with lower physical HRQoL (table 
3).  
The Durbin-Watson test coefficients for the mental and physical HRQoL models were less 
than 2.0 indicating that the residuals were uncorrelated. An analysis of the model residual plots 
against predicted values showed no patterns implying homogeneity of variance. The Q-Q plots 
showed a linear trend with only minor deviations at the upper tail, satisfying the assumptions of 
normality of residuals. Additionally, the variance inflation factors were below 1.2 meaning that 
there was no multicollinearity in the model. The predicted values were reasonable, within the 
range of the response variable indicating that the models fit the data. 
The Mediation Effect of Depression. 
Depression was not included in the models because we hypothesized that depression was 
a mediator of the relationship between impairment and HRQoL. To test this assumption, we used 
the approach in [53] to investigate the extent to which depression mediated the relationship 
between HIV neurocognitive impairment (NCI) and HRQoL using ordinary least squares in SAS 
version 9.4. To established mediation, NCI (independent variable) must be associated with 
depression (mediator), NCI must be associated with HRQoL (dependent variable) and depression 
must be associated with HRQoL [53, 55]. We regressed (a) depression on impairment (b) HRQoL 
on NCI (c) HRQoL on NCI controlling for depression and (d) depression on HRQoL.  
The results of the ordinary least squares regression show that NCI was negatively 
associated with depression (B = -1.583, p = 0.020) and depression was negatively associated 
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with mental (B = -0.450, p < 0.001) and physical HRQoL (B = -0.261, p < 0.001). Controlling for 
depression, neurocognitive impairment was associated with mental (B = 2.048, p = 0.005) and 
physical HRQoL ( B = 0.826, p = 0.528) although the relationship for physical health was not 
significant. The indirect effect of impairment on mental health (Sobel z = 2.236, p = 0.020) and 
physical health (Sobel z = 2.074, p = 0.038) as indicated by the Sobel test was significant. The 
proportion of the total effect mediated was higher for physical health (72.2%) than for mental 
health (51.5%). These results suggest that depression was a mediator of the relationship between 
HIV-associated NCI and mental and physical health related quality of life [53].  
There was a significant relationship between depression as measured by the Beck’s 
depression index and employment. Among participants with mild to severe depressive 
symptomatology, 78.1% were unemployed compared to 10.5% that were fully employed. Mild to 
severe depression was regarded as having a score of greater than 13 points on the Beck’s 
depression index. In crude analysis, being unemployed increases the odds of mild to severe 
depression by 2.83 (1.96 to 4.08) and being employed part-time increases the odds of mild to 
severe depression by 1.97 (1.20 to 3.21) compared to being fully employed. However, 
employment was not a mediator of the relationship between HIV-associated NCI and HRQoL  
(z = 1.603, p = 0.109). 
Discussion.  
Among HIV-positive CHARTER participants without confounding comorbidities we found 
a significant relationship between HIV-associated neurocognitive impairment (NCI) and health 
related quality of life (HRQoL). In unadjusted and adjusted analysis, impaired participants had 
significantly lower mental HRQoL scores compared to unimpaired participants. The results also 
suggest that impaired participants had lower physical HRQoL in crude analysis. The association 
between NCI and physical HRQoL remained negative when controlled for employment and other 
covariates but was no longer significant.  
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Unemployment was a stronger predictor of lower physical and mental HRQoL in this 
population than HIV-associated NCI. The strong association of employment with HRQoL may 
partly be explained by the association between employment and depression reflected in the 
mediation effect of depression on HIV-associated NCI and HRQoL. The beneficial effect of 
employment on depression and general mental health is well established. Employment has a 
protective effect on depression and general mental health and well-being [56, 57, 59], and 
psychological distress [58, 59]. Employment improves quality of life because it provides the 
means to acquire the necessities of life, improves consumption of goods and services, enhance 
economic and social status, and reduce physical and mental distress arising from worry 
associated with economic insecurity. 
In adjusted analysis, we also found that prescribed psychotropic drug use was significantly 
associated with mental HRQoL but not with physical health. Prescribed psychotropic medication 
use is partly induced by psychiatric problems such as depression. Some of the psychotropic drugs 
used to ameliorate the harmful health effects of psychiatric problems can affect cognitive function. 
Psychotropic drug use negatively affects memory, attention and psychomotor performance and 
is associated with lower cognitive scores in the elderly [62] and lower health related quality of life 
[60-63].  
The results of our study suggest that HRQoL significantly decreases with increasing 
severity of depression and depression mediates the relationship between HIV-associated NCI 
and HRQoL . This is consistent with findings from several studies that demonstrated that 
depression has a deleterious effect on mental health, role, emotional and social functioning of 
various patient groups [60, 61], decreases cognitive function [28] and mediates the relationship 
between NCI and HRQoL [53].  
In both unadjusted and adjusted analysis, opiate use was significantly associated with 
lower physical HRQoL but not with mental HRQoL. Participants with positive opiate test results 
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had significantly lower physical HRQoL compared to persons with a negative result. The 
association between opiate addiction, substance use and alcohol abuse and neurocognitive 
functioning are well established. Opiate addiction, chronic substance or alcohol abuse can 
aggravate the deleterious effect of HIV on brain metabolites and can lead to neuronal injury, 
affects neuropsychological functioning, alter health behavior and results in low levels of 
medication adherence [13- 15, 37, 64].  
With 30 million people projected to be on combination antiretroviral therapy (cART) by 
2020 (UNAIDS, 2016), and given the observed increase in life expectancy of HIV seropositive 
individuals on cART, the potential collective impact of HIV-associated NCI, depression, substance 
abuse, psychotropic medication use and unemployment on a large proportion of these population 
should be of serious concern. This is particularly important because HIV and age-related cognitive 
impairment, substance abuse and depression affect the individual’s ability to adhere to 
medication, perform activities of daily living, hold, or maintain a job, and live a normal productive 
life. HIV seropositive persons on cART are living longer implying that HIV is becoming a chronic 
disease, requiring continuous management. The combined effect of neurocognitive deficits, 
substance abuse, unemployment and depression are likely to contribute significantly to decline in 
HRQoL with significant impact on healthy aging. There is need to design specific interventions 
aimed at the optimal management and improvement in the quality of life of persons living with 
HIV, including the management of depression and maintenance of employment.  
In this study, HRQoL was conceptualized within the framework of the Medical Outcome 
Survey (MOS) questionnaire which measures HRQoL using 35 items that require individuals to 
provide a subjective evaluation of their health and wellbeing. The questionnaire was designed to 
measure11 scales of HRQoL (mental health, energy or fatigue, health distress, cognitive function, 
quality of life, pain, physical functioning, role functioning, social functioning, general health and 
health transition). Consistent with our secondary objectives and in harmony with previous 
research findings in [47], we established using factor analysis that the 35-item MOS questionnaire 
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can be summarized into two dimensions, physical and mental HRQoL and is a reliable and valid 
measure of HRQoL. 
Limitations 
The study has some limitations. First the CHARTER study was based on a volunteer 
sample comprising of individuals attending clinics in the study centers. This implies that the 
sample is not representative of HIV-patients in other clinics or patients who would not volunteer 
for such studies (see https://neuroaids-dcc.unmc.edu/CharterResDesc). To address this concern, 
and to ensure that the CHARTER sample was as inclusive as possible of the population of HIV 
participants visiting the study clinics, minimal exclusion criteria was used. Participants were 
recruited from six sites widely distributed within the United States.  
Data was collected using mix methods involving patient self-reports for outcome variable, 
and a mixture of clinician ratings and self- report for the exposure variable. This implies that the 
data is subject to mode effects. The relationship between neurocognitive impairment and quality 
of life is influenced by a mesh of factors, which confound , mediate or moderate the relationship. 
This may be a source of bias. To limit the impact of confounding on the analysis, structured 
approach to bias was applied by analyzing the various causal pathways of the relationship 
between the two variables. The directed acyclic graph (DAG) approach was used to identify the 
most important confounders and statistical tests were conducted with these variables to determine 
confounding effects.  
Conclusion 
We used baseline data from the prospective, observational CHARTER study to investigate 
the relationship between HIV-associated NCI, as measured by GDS, and HRQoL. We 
hypothesized that NCI is associated with lower physical and mental HRQoL and that NCI 
participants have lower HRQoL than unimpaired HIV participants in the CHARTER study. Our 
central hypothesis was supported in unadjusted and adjusted analysis for mental health, but the 
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inverse relationship between HIV associated neurocognitive impairment and physical HRQoL was 
no longer significant when adjusted for other covariates. Depression is a strong mediator of the 
relationship between HIV associated neurocognitive impairment and HRQoL. The implication of 
the mediation effect of depression is that in the CHARTER population, managing depression 
should be a potential target to lessen the risk of HIV neurocognitive impairment and improve 






Flow chart showing final sample sizes 
 
2,016 participants were screened for 
the CHARTER study   
   
 
  
     366 elected not to 
participate. 40 not asked to 
continue or did not 
meet criteria to 
continue. 
   
  
   
      
 1,610 participated in cross sectional 
study. 
  
   
      
23 Missing data on 
outcome variable. 
     
     
      
 
1,587 complete cases on outcome 
variable used in factor analysis for this 
study. 
  
   
   
 
  
     247 excluded from analysis 
due to confounding 
comorbidities   
   
       
1,340 cases without confounding 
comorbidities used for analysis. 
 
  
     
34 cases missing data 
on physical health 
confounding variables 
     
  
  275 cases missing data on 
mental health confounding 
variables     
      
1,306 complete case 
analysis on physical 
health for final model.     
1065 complete case 
analysis on mental health 
for final model.   






Path model of health-related quality of life of CHARTER participants (n = 1,587) 
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Single headed arrows show standardized path coefficients; Curved double headed arrow shows 
covariance for two factors. * p < 0.001. F1, Factor 1; F2, Factor 2;  V1…V10, represents variable name. 
 
  




























Means, standard deviations and Pearson correlation coefficients for the  health-related quality of 
life (HRQoL) scales of the medical outcome survey questionnaire (n=1,587). 
No Scales Mean SD 1 2 3 4 5 6 7 8 9 10 
1 Mental health  66.55 21.66 1                   
2 Energy/Fatigue 53.28 22.21  .66 1 
        
3 Health distress  72.10 26.33  .66  .57 1 
       
4 Cognitive 
function  
72.13 23.80  .59  .56  .59 1 
      
5 Quality of life  64.44 22.06  .59  .55  .50  .43 1 
     
6 Pain  66.24 26.73  .42  .52  .50  .41  .42 1 
    
7 Physical 
function  
69.02 27.47  .35  .49  .45  .43  .33  .58 1 
   
8 Role function  54.09 45.32  .38  .49  .47  .41  .36  .51  .55 1 
  
9 Social function  74.12 28.45  .53  .56  .60  .54  .44  .55  .58  .56 1 
 
10 General health  48.25 26.91  .52  .59  .60  .46  .56  .58  .52  .56  .54 1 
Note: Higher mean scores indicate better quality of life perception, lower pain and limitations in role 








The relationship between neurocognitive impairment and   mental-related quality of life (HRQoL) of CHARTER 
participants  
(n = 1,065). 
Variable n (%) 
Mental  HRQoL 
composite 
scores 






 (95% CI) 
     
Neurocognitive impairment (GDS)d p < 0.002  
 No 679 (63.8) 65.82 (18.82) ref ref 
 Yes 386 (36.2) 61.45 (18.11) -4.38 (-6.70 to -2.06) -2.56 (-4.83 to -0.30) 
Gender at Birth 
  p = 0.273  
 Male 807 (75.8) 64.59 (18.35)   
 Female 258 (24.2) 63.12 (19.66) -1.47 (-4.09 to 1.15) -2.14 (-4.75 to 0.46) 
 Age (years)   p = 0.571  
 ≤ 39 321 (30.2) 64.87 (19.08) ref ref 
 40-49 504 (47.3) 64.05 (18.38) -0.82 (-3.44 to 1.80) -0.11 (-2.65 to 2.42) 
 50-59 212 (19.9) 63.24 (18.35) -1.63 (-4.88 to 1.61) -0.09 (-3.22 to 3.04) 
 ≥ 60 28 (2.6) 67.74 (21.84) 2.86 (-4.36 to 10.09) 4.23 (-2.68 to 11.14) 
Race/Ethnicity    p = 0.001  
 Black or African 
American 
479 (45.0) 66.75 (18.07) 
ref ref 
 White 462 (43.4) 62.05 (18.97) -4.69 (-7.07 to -2.32) -5.86 (-8.28 to -3.44) 
 Hispanic 99 (9.3) 62.58 (17.56) -4.17 (-8.19 to -0.15) -4.17 (-8.09 to -0.25) 
 Other 25 (2.3) 63.09 (23.76) -3.66 (-11.13 to 3.81) -5.05 (-12.25 to 2.15) 
Employment   p < 0.001  
 Full time 152 (14.2) 71.96 (16.53) ref ref 
 Part-time 137 (12.9) 65.50 (18.57) -6.46 (-10.71 to -2.20) -6.64 (-10.78 to -2.50) 
 Not currently employed 776 (72.9) 62.50 (18.71) -9.46 (-12.66 to -6.26) -8.96 (-12.17 to -5.75) 
Current psychotropic medication use  p < 0.001  
 No 310 (29.1) 71.28 (16.21) ref ref 
 Yes 755 (70.9) 61.34 (18.86) -9.93 (-12.33 to -7.53) -8.21 (-10.63 to -5.80) 
n = sample size with percentage of respondents in bracket; ref means the reference category. aSD, Standard deviation, bCI, Confidence 









The relationship between HIV associated neurocognitive impairment and  physical health-related quality of life (HRQoL) 
of CHARTER participants (n = 1,306). 











(GDS)e     
p = 0.001 
  
 No 843 (64.5) 65.17 (25.04) ref ref 
 Yes 463 (35.5) 60.55 (24.92) -4.62 (-7.45 to -1.78) -2.20 (-4.81 to 0.40) 
Gender at Birth 
 
 
p  < 0.001 
 
 Male 1,008 (77.2) 65.00 (24.96) ref ref 
 Female 298 (22.8) 58.55 (24.92) -6.45 (-9.67 to -3.22) -6.53 (-9.57 to -3.49) 
 Age (years)   p  < 0.001  
 ≤ 39 422 (32.3) 70.60 (23.83) ref ref 
 40-49 594 (45.5) 61.42 (24.65) -9.19 (-12.25 to -6.12) -6.32 (-4.28 to -9.21) 
 50-59 254 (19.4) 56.43 (24.96) -14.17 (-18.00 to -10.35) -10.49 (-14.-8 to -6.91) 
 ≥ 60 36 (2.8) 65.50 (28.10) -5.11 (-13.47 to 3.26) -2.36 (-10.10 to 5.38) 
Race/Ethnicity   p = 0.606  
 Black or African 
American 
605 (46.3) 62.79 (23.98) 
ref ref 
 White 544 (41.7) 63.69 (26.23) 0.90 (-2.01 to 3.81) -4.45 (-7.22 to -1.68) 
 Hispanic 124 (9.5) 65.69 (24.30) 2.95 (-1.96 to 7.75) 0.51 (-3.93 to 4.96) 
 Other 33 (2.5) 66.22 (28.76) 3.42 (-5.38 to 12.23) -3.21 (-11.21 to 4.79) 
Employmente  
 
p < 0.001 
 
 Full time 222 (17.0) 82.31 (17.45) ref ref 
 Part-time 163 (12.5) 68.66 (21.23) -13.65 (-18.38 to -8.92) -11.95 (-16.58 to -7.33) 
 Not currently 
employed 
921 (70.5) 58.09 (24.91) -24.22 (-27.65 to -20.79) -21.97 (-25.44 to -18.50) 
Lowest CD4 count (cells/mm3)  p  < 0.001  
 ≥ 500 121 (9.3) 72.77 (24.49) ref ref 
 200-499 481 (36.8) 65.74 (25.84) -12.34 (-17.13 to -7.55) -6.08 (-10.60 to -1.56) 
 < 200 704 (53.9) 60.43 (24.13) -7.04 (-12.00 to -2.09) -7.20 (-11.64 to -2.77) 
Current opiate test results  
 
p  < 0.001  
 Positive 95 (7.3) 48.61 (24.92) ref ref 
 Negative 1,211 (92.7) 64.70 (24.73) 16.09 (10.91 to 21.26) 11.12 (6.35 to 15.90) 
n = sample size with percentage of respondents in bracket; ref means the reference category. aSD, Standard deviation, bCI, Confidence 









Table 4: CHARTERa study neuropsychological test battery by cognitive domain. 
Domain Test 
1.  Speed of Information 
 Processing 
Wechsler Adult Intelligence Scale [WAIS]-II Digit Symbol  
WAIS-III -Symbol Search 
 Trail Making Test Part A 
 2. Learning  Hopkins Verbal Learning Tests Revised [HVLT-R] Learning Trials 
Brief Visuospatial Memory Test Revised [BVMT-R] 
 Learning Trials  
Story Memory Test (Learning Component);  
Figure Memory Test (Learning Component) 
 
3.  Memory  HVLT-R Delayed Recall, BVMT-R Delayed Recall, 
 Story Memory Test (with delayed recall),  
Figure Memory Test (delayed recall component);  
Brief Visuospatial Memory Test Revised, 
 
4.  Executive Function 
 Category Fluency Test, 
Wisconsin Card Sorting Computerized Test [64-item version],  
Trail Making Test Part B  
5. Verbal Fluency Verbal Fluency-Controlled Oral Word Association Test [F-A-S 
letters] 
Category Fluency Test [animals]  
 6. Attention and Working 
Memory  
 Paced Auditory Serial Addition Test-50 
 WAIS-III Letter-Number Sequencing  
7. Motor Function 
 
Grooved Pegboard Test, Dominant and Non-Dominant Hands.  
 



















ap-value based on t-test, p-value >  0.05 means not significant,  SD, Standard deviation, CHARTER means , Central nervous system (CNS) HIV 
antiretroviral therapy effects research study. bMental and physical health-related quality of life composite scores were computed as factor-







Table 5  Differences in health-related quality of life (HRQoL) between HIV neurocognitive 
impaired and unimpaired CHARTER participants. 
Scales 
Impaired (n = 477) Unimpaired (n = 863) 
p-valuea 
Mean (SD) Mean (SD) 
Mental  
  Mental health 64.9 (21.5) 68.4 (21.2)  .004 
  Energy/Fatigue  51.4 (22.6) 54.9 (22.0)  .006 
  Health distress  70.8 (25.6) 75.0 (25.5)  .004 
  Cognitive function  69.4 (24.1) 75.9 (22.1) < .001 
  Quality of life 63.5 (22.2) 65.2 (21.5)  .175 
  Mental compositeb 64.0 (18.4) 67.9 (18.6) < .001 
Physical   
  Pain  65.6 (27.6) 67.7 (26.0)  .164 
  Physical function 65.5 (27.8) 72.7 (26.7) <.001 
  Role function 50.4 (45.6) 58.3 (45.0)  .002 
  Social function 72.3 (28.5) 76.5 (27.4)  .009 
  General health  47.9 (25.7) 50.2 (27.7)  .141 




1. Nightingale S, Winsto A, Letendre S, et al. Controversies in HIV-associated neurocognitive 
disorders. Lancet Neurol. 2014 ;13(11): 1139–1151. doi: 10.1016/S1474-4422(14)70137-
1 
2. Williams DW, Veenstra M, Gaskill PJ, Morgello S, Calderon TM, Berman JW. Monocytes 
mediate HIV neuropathogenesis: Mechanisms that contribute to HIV associated 
neurocognitive disorders. Curr. HIV Res.  2014; 12(2): 85–96. 
3.  McRae MP. HIV and viral protein effects on blood brain barrier. Tissue Barriers. 2016; 
4(1):   e1143543. doi: 10 .1080/2168837 .2016.1143543. 
4.  Spudich S, González-Scarano F. HIV-1 related central nervous system disease: current 
issues in pathogenesis, diagnosis and treatment. Cold Spring Harb Perspect Med. 2012; 
2(6): a00712 . doi: 10 .1101/cshperspect. a007120 
5. Jernigan TL, Archibald SL, Fennema-Notestine C, Taylor MJ, Theilmann RJ, Julaton MD 
et al. Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 
2011; 17(3):248-57. doi: 10 .1007/s13365-011-0032-7. 
6. Airoldi M, Bandera A, Trabattoni D, Tagliabue B, Arosio B, Soria A, et al. Neurocognitive 
impairment in HIV-infected naïve patients with advanced disease: the role of virus and 
intrathecal immune activation. Clin Dev Immunol. 2012; 2012():467154. 
7. Crews L, Patrick C, Achim CL, Everall IP, Masliah E. Molecular pathology of neuro-AIDS 
(CNS-HIV). International Journal of Molecular Science. 2009; 10(3):1045-63. doi: 10 
.3390/ijms10031045. 
8. Chen ZY, Shen FY, Jiang L, Zhao X, Shen XL, Zhong W, et al.  Attenuation of neuropathic 
pain by inhibiting electrical synapses in the anterior cingulate cortex. Anesthesiology. 
2016; 124(): 169-183. doi:10 .1097/ALN.0000000000000942. 
25 
 
9. Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson JH, et al. Cortical 
synaptic density is reduced in mild to moderate human immunodeficiency virus 
neurocognitive disorder. Brain Pathol. 1999; 9:209–217.  
10. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M,  et al. Dendritic injury 
is a pathologic substrate for HIV-related cognitive disorders. Ann Neurol. 1997; 42:963– 
972. 
11. Anderson AM, Fennema-Notestine C, Umlauf A, Taylor MJ, Clifford DB, Marra CM, et al. 
CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic 
resonance spectroscopy metabolites during chronic HIV disease. Journal of 
Neurovirology. 2015;21(5):559-67. doi: 10 .1007/s13365-015-0359-6.  
12. Churchill M, Nath A. Where does HIV hid? A focus on the central nervous system. Curr 
Opin HIV AIDS. 2013; 8(3): 165–169. doi: 10 .1097/COH.0b013e32835fc601. 
13. Chang L, Ernst T, Speck O, Grob CS. Additive effects of HIV and chronic 
methamphetamine use on brain metabolite abnormalities. Am J Psychiatry. 2005; 
162(2):361–369.  
14. Reiner BJ, Keblesh J P, Xiong H. Methamphetamine abuse, HIV infection, and 
neurotoxicity. 2009. Int J Physiol Pathophysiol Pharmacol. 2009; 1(2): 162–179. 
15. Rothlind JC, Greenfield TM, Bruce AV, Meyerhoff DJ, Flenniken DL, Lindgren JA, et al. 
Heavy alcohol consumption in individuals with HIV infection: effects on neuropsychological 
performance. J Int Neuropsychol Soc. 2005); 11(1):70–83. 
16. Hinkin CH, Castellon SA, Levine AJ, Barclay TR, Singer EJ. Neurocognition in individuals 
Co-infected with HIV and Hepatitis C. J Addict Dis. 2008; 27(2): 11–17. 
17. de Almeida SM, de Pereira AP, Pedroso MLA, Ribeiro CE, Rotta I, Tang B,  et al. 
Neurocognitive impairment with hepatitis C and HIV co-infection in Southern Brazil. J 
Neurovirol. 2018; 24(3):339-349. doi: 10.1007/s13365-018-0617-5. 
26 
 
18. Marra CM, Deutsch R, Collier AC, Morgellons S, Letendre S, Clifford D, et al. 
Neurocognitive impairment in HIV-infected individuals with previous syphilis. Int J STD 
AIDS. 2013; 24(5): 351-5. doi: 10.1177/0956462412472827. 
19.  Ho EL, Maxwell CL, Dunaway SB, Sahi SK, Tantalo LC, Lukehart SA,  et al. 
Neurosyphilis increases human immunodeficiency virus (HIV)-associated central nervous 
system inflammation but does not explain cognitive impairment in HIV-infected individuals 
with syphilis. Clinical Infectious Diseases. 2017; 65(6): 943–948, https://doi.org/1 
.1093/cid/cix473 
20. Becker JT, Kingsley L, Mullen J, Cohen B, Martin E, Miller EN, et al. Vascular risk factors, 
HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology. 2009; 
73(16):1292-9. doi: 10 .1212/WNL.0b013e3181bd10e7. 
21. Deckers K, Schievink SHJ, Rodriquez MMF, van Oostenbrugge RJ, van Boxtel 
MPJ, Verhey FRJ, et al. Coronary heart disease and risk for cognitive impairment or 
demential: Systematic review and meta-analysis. PLoS One. 2017; 12(9): e0184244. doi: 
1 .1371/journal.pone.0184244 
22. Deckers K, van Boxtel MP, Schiepers OJ, de Vugt M, Muñoz Sánchez JL, Anstey KJ, et 
al. Target risk factors for dementia prevention: a systematic review and Delphi consensus 
study on the evidence from observational studies. International Journal of Geriatric 
Psychiatry. 2015; 30: 234–246. 
23. Cournot M, Marquié JC, Ansiau D, Martinaud C, Fonds H, Ferrières J, et al.Relation 
between body mass index and cognitive function in health middle-aged men and women. 
Neurology. 2006; 10;67(7):1208-14. 
24. Sabia S, Kivimaki M, Shipley MJ, Marmot MG, Singh-Manoux A. Body mass index over 
the adult life course and cognition in late midlife: the Whitehal II cohort study. Am J Clin 
Nutr. 2009; 89(2):601-7. doi: 10 .3945/ajcn.2008.26482.  
27 
 
25. Taki Y, Kinomura S, Sato K, Inoue K, Goto R, Okada K, et al. Relationship between body 
mass index and gray matter volume in 1,428 healthy individuals. Journal of Obesity. 2008; 
16, 119–124. doi:10 .1038/oby.2007.4 
26. Okafor CN, Kelso NE,  Bryant V, Burrel LE,II, Míguez, MJ, Gongvatana A, et al. Body 
mass index, inflammatory biomarkers and neurocognitive impairment in HIV-infected 
persons. Psychol Health Med. 2017; 22(3): 289–302. doi: 10 
.1080/13548506.2016.1199887. 
27. Mascolini M. Lipid impact on HIV heart disease and antiretroviral impact on lipids. 2017; 
Retrieved from http://www.thebodypro.com/content/79780/lipid-impact-on-hiv-heart-
disease-and-antiretrovir.html. 
28. Trivedi JK. Cognitive deficits in psychiatric disorders: Current status. Indian Journal of  
Psychiatry. 2006; 48(1), 10–2 . http://doi.org/1 .4103/0019-5545.31613. 
29. Clark LD, Iversen SD, Goodwin G. Sustained attention deficit in bipolar disorder. Br J 
Psychiatry. 2002 ;180:313–19. 
30. Lebowitz BK, Shear PK, Steed MA, Strakowski SM.  Verbal fluency in mania: relationship 
to number of manic episodes. Neuropsychiatry Neuropsychol Behav Neurol. 2001; 
14(3):177-82. 
31. Okasha A, Rafaat M, Mahallawy N, El Nahas G, El Dawla AS, Sayed M, et al. Cognitive 
dysfunction in obsessive—compulsive disorder. Acta Psychiatr Scand. 2000; 101:281–5 
32. Paterniti S, Dufouil C, Bisserbe JC, Alpérovitch A. Anxiety, depression, psychotropic drug 
use and cognitive impairment. Psychol Med. 1999; 29(2):421-8. 
33. Becker JT, Maruca V, Kingsley LA, Sanders JM, Alger JR, Barker PB, et al. Factors 
affecting brain structure in men with HIV disease in the post-HAART era. Neuroradiology. 
2012; 54(2): 113–121. doi: 10.1007/s00234-011-0854-2 
28 
 
34. Grant I, Sacktor N. HIV-associated neurocognitive disorders. In H.E. Gendelman, I. Grant, 
I.P. Everall, H.S. Fox, H. A. Gelbard, S. A. Lipton & S. Swindells (Eds), The Neurology of 
AIDS (3rd ed pp 488-499). New York, NY 10016: Oxford University Press, Inc. 
35. Mutabazi-Mwesigire D, Katamba A, Martin F, Seeley J, Wu AW. Factors that affect quality 
of life among people living with HIV attending an urban clinic in Uganda: A cohort study. 
PLoS One. 2015;10(6): e012681 . doi: 1 .1371/journal.pone.012681 .  
36.  Bucciardini R, Pugliese K, Weimer L, Digregorio M, Fragola V, Mancini M, et al. 
Relationship between health-related quality of life measures and high HIV viral load in HIV 
–infected triple-class-experienced patients. HIV Clinical Trials, 15:4, 176-183, DOI: 10 
.1310/hct1504-176 
37. Daeppen JB, Krieg MA, Burnand B, Yersin B. MOS-SF-36 in evaluating health-related 
quality of life in alcohol-dependent patients. The American Journal of Drug and Alcohol 
Abuse. 2009; 24(4), 685-694, DOI: 1 .3109/00952999809019617 . 
38. Ko H, Lee J, Shin J, Jo E. Health-related quality of life and cardiovascular disease risk in 
Korean adults. Korean J Fam Med. 2015; 36(6): 349–356. doi: 10 
.4082/kjfm.2015.36.6.349. 
39. Katz DA, McHorney CA, Atkinson RL. Impact of obesity on health-related quality of life in 
patients with chronic illness. Journal of General Internal Medicine. 2000; 15(11), 789–796. 
http://doi.org/10 .1046/j.1525-1497.200 .90906.x 
40. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: 
increases in life expectancy among treated HIV-positive individuals in the United States 
and Canada. PLoS One. 2013; 8: e81355 
41. UNAIDS. Joint United Nations Program me on HIV/AIDS. AIDS by the number: AIDS is 




42. CHARTER Study description. Retrieved from https://neuroaids-
dcc.unmc.edu/CharterResDesc 
43. Matcham F, Norton S, Streer S, Hotopf M . Usefulness of the SF-36 health survey in 
screening for depressive and anxiety disorders in rheumatoid arthritis BMC Musculoskelet 
Disord. 2016; 17: 224. doi: 10 .1186/s12891-016-1083-y 
44. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, et al. HIV-associated 
neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER 
Study. Neurology.2010;75(23):2087-2096. 
45. Blackstone K, Moore DJ, Franklin DR, Clifford DB, Collier AC, Marra CM, et al. Defining 
neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol. 
2012;26(6):894-908. doi: 10 .1080/13854046.2012.694479.  
46. Gurková E. Issues in the definition of HRQoL. Journal of Nursing, Social Studies, Public 
Health and Rehabilitation. 2011; 3–4: 190–197. Retrieved from http://casopis-
zsfju.zsf.jcu.cz/journal-of-nursing-social-studies-public-health-and-
rehabilitation/administrace/clankyfile/20120430140614748509.pdf 
47. Revicki DA, Sorensen S, Wu AW. Reliability and validity of physical health and mental 
health summary scores from the MOS HIV Health Survey. Medical Care. 1998; 36 (2):126-
137. 
48. O’Rourke N, Hatcher L. A Step-by-Step Approach to Using SAS® for Factor Analysis and 
Structural Equation Modeling, Second Edition. Copyright © 2013, SAS Institute Inc., Cary, 
North Carolina.  
49. Bearden WO, Sharma S, Teel JE. Sample Size Effects on Chi Square and Other Statistics 
Used in Evaluating Causal Models. Journal of Marketing Research. 198; 19(4). 425-43 . 
50. Hu LT, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: 
Conventional criteria versus new alternatives, Structural Equation Modeling: A 
Multidisciplinary Journal. 1999 6:1, 1-55. http://dx.doi.org/1 .1080/10705519909540118 
30 
 
51. Marsh HW, Hau K, Wen Z. In search of golden rules: Comment on hypothesis-testing 
approaches to setting cutoff values for fit Indexes and dangers in overgeneralizing Hu and 
Bentler's (1999) findings. Structural Equation Modeling. 2004; 11:3, 320-341, DOI: 10 
.1207/s15328007sem1103_2. 
52. Greenlan S, Daniel R, Pearce N. Outcome modelling strategies in epidemiology: 
traditional methods and basic alternatives.  Int J Epidemiol. 2016 Apr; 45(2): 565–575. 
doi: 10.1093/ije/dyw040 
53. Shresthaa R,  Weikum D,  Copenhaver M,  Altice FL. The Influence of neurocognitive 
impairment, depression, and alcohol use disorders on health-related quality of life among 
incarcerated, HIV-infected, opioid dependent Malaysian men: A moderated mediation 
analysis. AIDS Behav. 2017 April ; 21(4): 1070–1081. doi:10.1007/s10461-016-1526-3. 
54. Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in 
detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004 
May;26(3):307-19. 
55. Baron  RM, Kenny DA.  The moderator-mediator variable distinction in social psychological 
research: conceptual, strategic, and statistical considerations . Journal of Personality and 
Social Psychology. 1986, Vol. 51, No. 6, 1173-1182. 
56. Van der Noordt M, IJzelenberg H, Droomers M, Proper K I. Health effects of employment: a 
systematic review of prospective studies. Occupational and Environmental Medicine, 2014. 
71(10). http://dx.doi.org/10.1136/oemed-2013-101891 . 
57. Liira J, Leino-Arjas P.  Predictors and consequences of unemployment in construction and 
forest work during a 5-year follow-up. Scand J Work Environ Health 1999;25: 42–9. Retrieved 
from https://www.jstor.org/stable/pdf/40966862.pdf. 
58. Lahelma E.  Unemployment and mental well-being: elaboration of the relationship. Int J 
Health Serv 1992;22:261–74. 
31 
 
59. Graetz B. Health consequences of employment and unemployment: Longitudinal 
evidence for young men and women. Elsevier, Science and Medicine 36 (6) 1993, 715-
724. https://doi.org/10.1016/0277-9536(93)90032-Y 
60. Brenes GA. Anxiety, depression and quality of life in primary care patients.Prim Care 
Companion J Clin Psychiatry. 2007; 9(6): 437–443. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2139931/ 
61. Wells KB, Sherbourne CD. Functioning and utility for current health of patients with 
depression and chronic medical conditions in managed primary care practices. Arch 
Gen Psychiatry. 1999 Oct;56(10):897-904. 
62. Paterniti, S., Dufouil, C., Bisserbe, J.C., Alpérovitch, A. (1999). Anxiety, depression,  
psychotropic drug use and cognitive impairment. Psychol Med.;29(2):421-8. 
63. Mutabazi-Mwesigire, D. Katamba, A. Martin, F., Seeley, J., Wu, A.W., (2015). Factors that 
affect  quality of life among people living with HIV attending an urban clinic in Uganda: A 
cohort study. PLoS One. 2015 3;10(6): e0126810. doi: 10.1371/journal.pone.0126810.  
64. Nath A. Human immunodeficiency virus-associated neurocognitive disorder: 
pathophysiology in relation to drug addiction. Ann N Y Acad Sci. 2010;1187:122-8. doi: 
10.1111/j.1749-6632.2009.05277.x. 
 
 
